17,261 trials
COVID-19
Primary: Incidence of Mortality — 32; 26 Participants — p=0.1885
Locally Advanced or Metastatic Pancreatic Cancer
Primary: Overall Tumor Response Rate (ORR) — 4.0; 9.5 percentage of participants
Liver Transplant · Kidney Transplant
Primary: Tacrolimus Target Trough Level Maintenance — 38.4; 24.2 percentage of days
Recurrent Pleural Malignant Mesothelioma · Stage IV Pleural Mesothelioma
Primary: Progression-free Survival (PFS) — 1.8 months
Melanoma
Primary: Number of Participants With Optimal Biological Dose (OBD) of LL37 Based Upon Toxicity — 2; 1 Participants
Duchenne Muscular Dystrophy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation From Study Drug — 9; 6; 0; 1…
Opioid-use Disorder
Primary: Successful Vivitrol Induction — 10 Participants
Prosthetic Joint Infection
Primary: Safety Evaluations: Number and Frequency of Adverse Events Among Participants — 14; 14; 14; 14 Participants
Primary Hyperoxaluria
Primary: Change in Pre Dialysis Plasma Oxalate (Total Plasma Oxalate) Level During Treatment With OC5 Compared With Baseline. — 147.57; 11.34; 7.46; -5.68 μmol/L
Stress Disorders, Post-Traumatic
Primary: Change From Baseline in Clinician-Administered Post-traumatic Stress Disorder (PTSD) Scale for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)…
Cystic Fibrosis
Primary: Part 1: Absolute Change From Baseline in MRI Global Chest Score at Week 48 — -0.3; -1.7 score on a scale
Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency · Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency · Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency
Primary: Annualized LC-FAOD Major Clinical Events (MCEs) Rate: 18 Months Pre- and Entire UX007 Period Comparison for UX007-CL201-Rollover Cohort — 1.76; 1.00 events/year — p=0.0347
Anxiety
Primary: Baseline State-Trait Anxiety Inventory (STAI) — 53.1; 47.7; 53.2; 43.3 score on a scale
Atrial Fibrillation
Primary: Number of Participants That Achieved More Than or Equal to 50%, 80%, and 90% Factor XI Inhibition at Trough After the Third Dose (Day 91) at Different Dose Levels of…
Acute Pancreatitis · Systemic Inflammatory Response Syndrome
Primary: The Safety and Tolerability of CM4620-IE in Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome (SIRS) or Hypoxemia. — 7; 5; 3; 0…